4g34

Publication Abstract from PubMed

PKR-like Endoplasmic Reticulum Kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small molecule inhibitors. Through screening and lead optimization using the human PERK crystal structure, we discovered compound 38 (GSK2606414), an orally available, potent and selective PERK inhibitor. Compound 38 inhibits PERK activation in cells and inhibits the growth of a human tumor xenograft in mice.

Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of PKR-like Endoplasmic Reticulum Kinase (PERK).,Axten JM, Medina JR, Feng Y, Shu A, Romeril S, Grant S, Li WH, Heerding DA, Minthorn E, Mencken T, Atkins C, Liu Q, Rabindran S, Kumat R, Hong X, Goetz A, Stanley TB, Taylor D, Sigethy S, Tomberlin GH, Hassell A, Shewchuk LM, Gampe R J Med Chem. 2012 Jul 24. PMID:22827572^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.